|
Glioma
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Glioma
|
0.700 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Glioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
<b>Results</b>: We found that PD-L2 expression level was significantly upregulated in higher grade glioma and IDH wild-type glioma.
|
30713802 |
2019 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
<i>In vitro</i> studies revealed good binding inhibition potency and binding affinity for [<sup>18</sup>F]<b>1</b> in IDH1 mutant glioma cell lines, with a half-maximal inhibitory concentration value (IC<sub>50</sub>) of 54 nM and an equilibrium dissociation constant (<i>K</i><sub>d</sub>) of 40 nM.
|
30034587 |
2018 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
<sup>1</sup> H-MRS enables non-invasive detection of 2-hydroxyglutarate (2-HG), an oncometabolite accumulating in gliomas carrying mutations in the isocitrate dehydrogenase (IDH) genes.
|
30457203 |
2019 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
<sup>11</sup>C-METH PET parameters are significantly correlated with histological grade and IDH1 mutation status in patients with glioma.
|
28110346 |
2017 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
<sup>18</sup>F-DOPA uptake does not correlate with IDH mutation status and 1p/19q co-deletion in glioma.
|
30607877 |
2019 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
1p/19q co-deletion and IDH1 mutation status) in WHO grade II and III diffuse gliomas remains controversial.
|
28547590 |
2017 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
1p/19q codeletion and IDH1 mutations are also useful to support and extend the histological classification of gliomas since they are strongly linked to oligodendroglial morphology and grade II/III gliomas, as opposed to glioblastoma, respectively.
|
20862485 |
2010 |
|
Glioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
5-Hydroxymethylcytosine (5hmC) is implicated in glioma pathogenesis; however, its role in IDH1 mutant gliomas is incompletely understood.
|
29428975 |
2018 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha.
|
19359588 |
2009 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Glioma-derived mutations in IDH: from mechanism to potential therapy.
|
20510884 |
2010 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Gliomas with IDH1 or IDH2 mutation have better outcomes than do gliomas with wild-type IDH.
|
25495392 |
2015 |
|
Glioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Glioma grading can be differentiated and IDH1 mutational status can be predicted using IVIM.
|
31014573 |
2019 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
LHGDN |
IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors.
|
19117336 |
2009 |
|
Glioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors.
|
19117336 |
2009 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas.
|
19435942 |
2009 |
|
Glioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
IDH1 codon 132 sequencing was performed in a series of 404 patients with glioma (100 grade 2, 121 grade 3, and 183 grade 4 gliomas) and correlated with histology, genomic profile, methylguanyl methyltransferase (MGMT) promoter methylation status, and outcome.
|
19636000 |
2009 |
|
Glioma
|
0.700 |
Biomarker
|
disease |
CTD_human |
IDH1 mutations are a novel positive prognostic factor in anaplastic gliomas, with a favorable impact stronger than that of 1p/19q codeletion or MGMT promoter methylation.
|
19901110 |
2009 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
IDH1 and IDH2 mutations define a specific subtype of gliomas and may have significant utility for the diagnosis, prognosis, and treatment of patients with these tumors.
|
19996293 |
2009 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
IDH mutations in glioma and acute myeloid leukemia.
|
20692206 |
2010 |
|
Glioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
IDH mutations are a favorable prognostic factor for human glioma and can be used as biomarker for differential diagnosis and subclassification rather than predictor of response to treatment.
|
22002076 |
2011 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.
|
22343889 |
2012 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
IDH mutations in human glioma.
|
22748659 |
2012 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
IDH1 mutations are frequent genetic alterations in low-grade diffuse gliomas and secondary glioblastoma (GBM).
|
22904127 |
2012 |